纳西他马布用于复发性/耐火性神经母细胞瘤
Teresa Herriage1, Jawhar Rawwas1, Adam Sterman2
1Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, MN, USA.
Journal of pediatric hematology/oncology nursing
|February 19, 2026
概括
纳西他马布免疫疗法可以在复发/耐药神经母细胞瘤的门诊环境中安全地使用. 跨学科的团队方法有效地管理不良事件,允许患者在同一天接受治疗并返回家园.
科学领域:
- 儿科瘤学 儿科瘤学
- 免疫治疗是一种免疫疗法.
- 临床药房 临床药房
背景情况:
- 复发性/耐药性 (R/R) 神经母细胞瘤由于疾病耐药性而带来了重大治疗挑战.
- 纳西他马布是一种针对GD2的单克隆抗体,已被批准用于R/R高风险神经母细胞瘤.
- 严重的神经疼痛是与naxitamab治疗相关的显着不良事件.
研究的目的:
- 介绍naxitamab,一种用于R/R神经母细胞瘤的免疫疗法.
- 讨论与naxitamab相关的不良事件 (AE).
- 描述一种在门诊输液中心管理naxitamab的机构方法.
主要方法:
- 由由儿科瘤高级实践护士领导的跨学科团队制定标准化,可适应的护理计划.
- 包括各种各样的角色:护理,医生专家,药剂师,心理社会工作人员,患者和家庭.
- 为每个团队成员提供关于他们定义的责任的全面教育.
主要成果:
- 在纳西他马布输注过程中对不良事件的有效管理.
- 在门诊输液中心在多个治疗周期中安全地使用naxitamab.
- 患者在输液完成后2小时内被送回家.
结论:
- 门诊naxitamab的管理需要精心规划和执行由一个准备好的跨学科团队.
- 这种门诊护理模式提高了患者和家人的生活质量.
- 成功管理AE支持门诊免疫治疗的可行性.
相关概念视频
02:56Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
827
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
827